Twist's SARS-CoV-2 quality controls added to FDA materials

By The Science Advisory Board staff writers

March 26, 2020 -- Twist Bioscience's synthetic SARS-CoV-2 RNA quality controls for the development, verification, and validation of diagnostic tests for SARS-CoV-2 are now included in the U.S. Food and Drug Administration's (FDA) reference materials.

Twist offers two fully synthetic SARS-CoV-2 RNA distinct reference sequences as positive controls for the development of both next-generation sequencing and reverse transcription polymerase chain reaction assays. The following controls also can be used to determine the limit of detection and monitor of day-to-day test variations:

  • Twist Synthetic SARS-CoV-2 RNA Control 1 (MT007544.1)
  • Twist Synthetic SARS-CoV-2 RNA Control 2 (MN908947.3)

The Twist synthetic controls are designed based on two specific SARS-CoV-2 variants and cover the full viral genome and are sequence-verified.

Twist Bioscience partners with Miroculus on clinical products
Synthetic biology company Twist Bioscience announced on February 25 that it has initiated a collaboration with digital microfluidics developer Miroculus...

Copyright © 2020 scienceboard.net


Conferences
International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter